Charles Lin, PhD

VP of Business Development

Charles joined Element after more than 12 years at Illumina, where he served in a variety of research and development (R&D) and business roles. Most recently, he was Associate Director, Corporate and Business Development, focusing on mergers and acquisitions (M&A), investments, and emerging business areas. He led the $100 million acquisition of Edico Genome in 2018, and played a key role in the proposed $1.2 billion acquisition of Pacific Biosciences (terminated).


Previously at Illumina, Charles worked for over 10 years in product development for research and in vitro diagnostics markets. He led cross-functional teams to develop and commercialize a wide range of microarray and sequencing applications for use in genetic research, oncology, transplant medicine, pharmacogenomics, microbiology, and single-cell research. 


Charles holds a PhD in Chemistry and Chemical Biology from Harvard University, and was an American Heart Association Postdoctoral Fellow in Cell Biology at the University of California San Diego School of Medicine.